Cogent Biosciences, Inc.
Tremor tracks 4 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
Trials
- COGTCogent Biosciences, Inc.10Calm
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Running, no new patientsPhase 2237 patientsMain results: May 22, 2025 - COGTCogent Biosciences, Inc.10Calm
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Signing up patientsPhase 2140 patientsMain results: Sep 19, 2025 - COGTCogent Biosciences, Inc.10Calm
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Signing up patientsPhase 3482 patientsMain results: Sep 30, 2025 - COGTCogent Biosciences, Inc.0Calm
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
Running, no new patientsPhase 1/2110 patientsMain results: Mar 2027
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
2 sales (0 not pre-planned) · 0 purchases
- Morris ArleneBoard member · Aug 27, 2026Sold 42,349 sharesabout $1.6 million · pre-planned
- Morris ArleneBoard member · Aug 27, 2026Sold 3,161 sharesabout $119 thousand · pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.